Plavix News and Research

RSS

New chemical reaction creates a faster, simpler way of making tertiary amines for medicines

A University of Illinois at Urbana-Champaign research team has discovered a way to produce a special class of molecule that could open the door for new drugs to treat currently untreatable diseases.

15 Apr 2022

Anti-platelet drug class fails to extend survival in moderately ill COVID-19 patients

A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or lessen disease severity in patients with COVID-19 who were hospitalized but had a relatively moderate case, a new study finds.

15 Nov 2021

Precision medicine can determine the best drug treatment for severe heart disease

Is personalized medicine cost-effective? University of Alabama at Birmingham researcher Nita Limdi, Pharm.D., Ph.D., and colleagues across the United States have answered that question for one medical treatment.

15 May 2020

Rush University Medical Center offers new FDA-approved treatment for brain aneurysms

Rush University Medical Center is offering a newly FDA-approved treatment for brain aneurysms that is safer for patients and has a shorter recovery period than other treatments.

12 Jul 2019

UW researchers create novel system to measure platelet function

Emergency room doctors often have only a few minutes to determine which patients are in need of a blood transfusion.

13 Mar 2019

Patients taking anti-depressants more likely to develop gastrointestinal bleeding

Patients taking anti-depressant medications classified as selective serotonin reuptake inhibitors are 40 percent more likely to develop severe gastrointestinal bleeding, particularly when they also use common over-the-counter pain relievers, according to a research review in the Journal of the American Osteopathic Association.

31 Jan 2019

Study aims to understand role of clopidogrel in patients with cardiovascular disease

Platelet inhibition with aspirin is the cornerstone of medical therapy for coronary artery disease. In the era of percutaneous coronary intervention with drug-eluting stents, dual anti-platelet therapy with the addition of clopidogrel became the mainstay of therapy.

11 Sep 2018

Mono-antiplatelet therapy after aortic heart valve replacements may work as well as two drugs

Current treatment guidelines say patients who undergo minimally invasive aortic heart valve replacements should receive two antiplatelet drugs to reduce the risk of dangerous blood clots.

14 Aug 2018

Taking clot-preventing drug with aspirin may lower risk of major stroke, finds study

The research was part of the Platelet-Oriented Inhibition in New TIA and minor ischemic stroke trial -- a randomized, double-blind, placebo-controlled trial conducted between May 2010 and December 2017.

16 May 2018

Therapeutic small molecules safely prevent blood clots without excessive bleeding

It may be possible to disrupt harmful blood clots in people at risk for heart attack or stroke without increasing their risk of bleeding, according to a new study published in Nature Communications.

31 May 2017

Scientists use new technique to improve accuracy of detecting protein microcrystals

In a collaborative study, scientists from MIPT and JINR (Joint Institute for Nuclear Research) have increased the accuracy of detecting valuable protein crystals measuring just a few microns.

20 Oct 2016

New study to examine genomics of anti-platelet therapy after coronary interventions

Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.

29 Jul 2016

Overcoming barriers to move beyond race-based treatment decisions

Prescribing certain medications on the basis of a patient's race has long come under fire from those uneasy with using race as a surrogate for biology when treating disease.

28 May 2016

Medical scientists examine potential new tool for helping prevent stroke, heart attack

Medical scientists just vetted a potentially powerful new tool for helping prevent stroke and heart attack. In a study recently published in the New England Journal of Medicine, researchers show that a drug reduced the risk of stroke or heart attack by almost a quarter in patients who had previously suffered a stroke or mini-stroke.

26 Feb 2016

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the results from their real-world study XALIA showing that, in people with deep vein thrombosis (DVT), the rates of major bleeding and recurrent blood clots for XARELTO (rivaroxaban) in routine clinical practice were generally consistent with those observed in Phase 3 research.

7 Dec 2015

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF).

1 Sep 2015

Substantial pharmacogenetic information available on cardiovascular drugs

There is a wealth of published information describing interactions between drugs used to treat cardiovascular disease and the genetic variations that can affect how patients respond to them. But few heart specialists make routine use of this potentially life-saving data.

2 Jun 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

TSRI chemists develop innovative method for building new drug molecules

Chemists at The Scripps Research Institute have developed a broadly useful technique for building new drug molecules and other chemical products.

12 Mar 2015

Researchers find key protein critical to the success of common anti-platelet drug Plavix

Researchers at the UNC School of Medicine have found that the blood platelet protein Rasa3 is critical to the success of the common anti-platelet drug Plavix, which breaks up blood clots during heart attacks and other arterial diseases.

24 Feb 2015